

CONTENTS

You should rely only on the information contained in this prospectus to make your investment decision.

Sino Biopharmaceutical Limited has not authorised anyone to provide you with information that is different from what is contained in this prospectus.

Any information or representation not made in this prospectus must not be relied on by you as having been authorised by Sino Biopharmaceutical Limited, DBS Asia, other Underwriters, the directors of any of them, or any other parties involved in the Placing.

	<i>Page</i>
DEFINITIONS	1
GLOSSARY OF TECHNICAL TERMS	6
SUMMARY	
Business	8
Competitive advantages	10
Business strategy	11
Business objectives	13
Risk factors	14
Trading record	16
Use of proceeds	17
Profit forecast for the year ending 31 December, 2000	18
Placing statistics	19
Moratorium period applicable to the Initial Management Shareholders	20
Shareholders of the Company following completion of the Reorganisation	21
RISK FACTORS	
Risks relating to the business of Group	22
Risks relating to the industry	28
Risks relating to the PRC	30
Risks relating to the Shares	32
Issues to consider in relation to certain statements made in this prospectus	33
WAIVERS FROM STRICT COMPLIANCE WITH THE GEM LISTING RULES AND THE COMPANIES ORDINANCE	
Waiver on share disposal restriction under the GEM Listing Rules	34
Waiver on the requirement of financial period reported on under the Companies Ordinance	35

CONTENTS

	<i>Page</i>
INFORMATION ABOUT THIS PROSPECTUS AND THE PLACING	
Directors' responsibility for the contents of this prospectus	36
Placing Shares are fully underwritten	36
Placing Shares to be offered in Hong Kong only	36
Application for listing on GEM	37
Professional tax advice recommended	38
Stamp duty	38
Conditions of the Placing	38
DIRECTORS AND PARTIES INVOLVED IN THE PLACING	39
CORPORATE INFORMATION	42
INDUSTRY OVERVIEW	
Background of development of pharmaceutical industry	43
Regulations governing the pharmaceutical industry in the PRC	45
Good Manufacturing Practice	50
Import and export	51
Price control	51
State Basic Pharmaceuticals Catalogue	51
National Out-patient Medicines Catalogue	52
Medicare insurance system	52
Environmental protection	52
E-commerce	53
Prospects of the pharmaceutical production industry in the PRC	53
GENERAL OVERVIEW OF THE GROUP	
Introduction	56
History and development	56
Corporate structure	59
Business of the Group	
Biopharmaceutical business	60
Active business pursuits in the Group's biopharmaceutical business	76
Modernised Chinese medicine and chemical medicine business	79
Active business pursuits in the Group's modernised Chinese medicine and chemical medicine businesses	94
Insurance	97

CONTENTS

	<i>Page</i>
Environmental protection	97
Year 2000 computer compliance	97
STATEMENT OF BUSINESS OBJECTIVES	
Business strategy	98
Bases and assumptions	99
Implementation plans	100
Use of proceeds	109
DIRECTORS, SENIOR MANAGEMENT AND STAFF	
Directors	110
Senior management	111
Audit committee	112
Staff	113
Company's relationship with staff	113
COMPETING BUSINESSES OF THE INITIAL MANAGEMENT SHAREHOLDERS AND NON-COMPETITION UNDERTAKING	
Competing businesses	114
Non-competition undertaking	115
CONNECTED TRANSACTIONS	116
RELATIONSHIP WITH SHANDONG BIOPHARMACEUTICAL AND JIANGSU TIANQING	
Relationship with Shandong Biopharmaceutical	117
Relationship with Jiangsu Tianqing	118
SUBSTANTIAL SHAREHOLDERS, INITIAL MANAGEMENT SHAREHOLDERS AND SIGNIFICANT SHAREHOLDERS	
Substantial shareholders	119
Initial Management Shareholders	120
Significant shareholders	120
UNDERTAKINGS GIVEN BY THE INITIAL MANAGEMENT SHAREHOLDERS	
Non-disposal undertakings and escrow arrangement	121
Other undertakings	121

CONTENTS

	<i>Page</i>
SHARE CAPITAL	122
FINANCIAL INFORMATION	
Indebtedness	124
Liquidity, financial resources and capital structure	125
Trading record	125
Rules 17.15 to 17.21 of the GEM Listing Rules	133
Property interests	133
Profit forecast, dividend policy and working capital	134
Distributable reserves	135
Adjusted net tangible assets	136
No material adverse change	137
UNDERWRITING	
Underwriters	138
Underwriting arrangements and expenses	138
STRUCTURE AND CONDITIONS OF THE PLACING	
Issue Price	141
Conditions	141
The Placing	141
Stabilisation and Over-allotment Option	141
Commencement of dealings in the Shares	142
Shares will be eligible for CCASS	142
APPENDICES	
I. ACCOUNTANTS' REPORT	143
II. PROFIT FORECAST	163
III. PROPERTY VALUATION REPORT	166
IV. SUMMARY OF THE CONSTITUTION OF THE COMPANY AND CAYMAN ISLANDS COMPANY LAW	181
V. STATUTORY AND GENERAL INFORMATION	199
VI. DOCUMENTS DELIVERED TO THE REGISTRAR OF COMPANIES AND DOCUMENTS AVAILABLE FOR INSPECTION	228